Does sacubitril/valsartan improve outcomes compared to enalapril in patients with chronic Chagas cardiomyopathy and HFrEF?
Baseline data from the PARACHUTE-HF trial demonstrates that patients with Chagas cardiomyopathy-related HFrEF have a distinct clinical profile, emphasizing the need for dedicated treatments in this population.
Baseline characteristics of this study highlight the unique clinical profile of patients with CCC-related HFrEF, including the high proportion of women affected, lower rates of comorbidities (hypertension/diabetes) and higher prevalence of stroke and pacemaker implantation when compared with other non-CCC-related HFrEF studies. These findings reinforce the need for dedicated heart failure treatments in this neglected subpopulation, particularly in Latin America where Chagas disease remains a significant public health issue.
Echeverría et al. (Mon,) studied this question.